Search

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

201 questions · 202 findings · 84 reviews

No studies found 202 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Buspirone vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Ginkgo biloba vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

HYPNOSIS or RELAXATION vs TAU

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or…

The review found no eligible studies for this question.

1 finding from 1 review

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Switch to a specific antipsychotic vs switch to a different specific antipsychotic

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

PIMOZIDE vs antipsychotics

Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses

The review found no eligible studies for this question.

1 finding from 1 review

PIMOZIDE vs placebo

Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses

The review found no eligible studies for this question.

1 finding from 1 review

Amantadine vs placebo

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review